All News

As people who have "been there, done that," our very presence provides a new arrival on the cancer rollercoaster a sense of stability and certainty.

At the MPN Heroes Event, Olympic skater Scott Hamilton discusses importance of advocacy and research.

I would tune out or give an unsympathetic nod when I would hear people talk about anxiety because I didn't understand what it really was or how paralyzing it could be. That was until I got cancer.

Recent research found that some patients with lung cancer have misconceptions about their prognosis, as well as how palliative care can help.

Learn to incorporate healthy foods into your diet as part of a wellness warrior lifestyle.

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.

While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.

Wouldn't it be nice to forget a cancer diagnosis?

The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.

November is Lung Cancer Awareness Month, and our Lung Cancer Special Issue is offering new insights into the treatment of the disease.

Forgiveness is more than just words, it's feelings. Learning how to forgive others can help us in our cancer journey as well.

These are my thoughts on religion and cancer, but they may not be yours. Either way, I ask you to keep an open mind.

Even living in a country with socialized medicine, cancer debt is an unfortunate side effect of treatment, making holiday shopping a challenge

Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.

Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

A smartphone app helped significantly reduce pain and hospital visits for patients with metastatic solid tumors.

Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.

My pre-Thanksgiving trip for a new prosthesis is successful.

The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

To receive payment for counseling and increase access to services, a new bill has been introduced so that genetic counselors receive payment for counseling Medicare beneficiaries.

Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.

Although immunotherapies show promise for patients, there are still challenges ahead.

When I was first diagnosed, I searched for the stories that would give me hope in the darkness that surrounded me. Seven years later, I continue to pay it forward by putting my own story out there for the next person who needs it to find.

Partners who remain close during cancer-related discussions may protect the person with the disease from experiencing increased symptom burden.

The Food and Drug Administration (FDA) approved Daurismo (glasdegib) plus low-dose cytarabine (LDAC) chemotherapy to treat older, newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy.

A Venclexta combination was granted an accelerated approval to treat older patients with acute myeloid leukemia who are ineligible for chemotherapy.

The Food and Drug Administration (FDA) granted a priority review to quizartinib for the treatment of patients with relapsed or refractory FLT3-ITD acute myeloid leukemia (AML).